Community heroes or "high-risk" pariahs? Reasons for declining to enroll in an HIV vaccine trial

Vaccine

Volumn 26, Issue 8, 2008, Pages 1091-1097

  Newman, Peter A ^a   Daley, Andrea ^a   Halpenny, Roberta ^b   Loutfy, Mona ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b MAPLE LEAF MEDICAL CLINIC   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Behavioral disinhibition; Clinical trials; False positive reactions; HIV vaccines; Populations at risk; Research subject recruitment

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; ARTICLE; COMPUTER PROGRAM; EMOTION; FEMALE; FOLLOW UP; HEALTH INSURANCE; HUMAN; LABORATORY DIAGNOSIS; MALE; MEDICAL RECORD; MEDICAL RESEARCH; PERCEPTIVE DISCRIMINATION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RISK ASSESSMENT; SOCIAL ASPECT; SOCIAL PSYCHOLOGY; STIGMA; THEMATIC ANALYSIS;

ADOLESCENT; ADULT; AIDS VACCINES; CLINICAL TRIALS AS TOPIC; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; QUESTIONNAIRES; VACCINATION;

EID: 39149111257     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.12.016     Document Type: Article

References (15)

1. Mills E., Cooper C., Guyatt G., Gilchrist A., Rachlis B., Sulway C., et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS 18 (2004) 2235-2242
2. Buchbinder S.P., Metch B., Holte S.E., Scheer S., Coletti A., and Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial. J Acquir Immune Defic Syndr 36 (2004) 604-612
3. Halpern S.D., Metzger D.S., Berlin J.A., and Ubel P.A. Who will enroll? Predicting participation in a phase II AIDS vaccine trial. J Acquir Immune Defic Syndr 27 (2001) 281-288
4. Allen M., Israel H., and Rybczyk K. Trial-related discrimination in HIV vaccine clinical trials. AIDS Res Hum Retroviruses 17 (2001) 667-674
5. Newman P.A., Duan N., Roberts K.J., Seiden D., Rudy E.T., Swendeman D., et al. HIV vaccine trial participation among ethnic minority communities. J Acquir Immune Defic Syndr 41 2 (2005) 210-217
6. Newman P.A., Duan N., Lee S.-J., Rudy E.T., Seiden D., Kakinami, et al. Willingness to participate in HIV vaccine trials among communities at risk: the impact of trial attributes. Prevent Med 44 6 (2007) 554-557
7. Charmaz K.C. Constructing grounded theory: a practical guide through qualitative analysis (2006), Sage Publications, Thousand Oaks
8. Glaser B.G. Theoretical sensitivity: advances in the methodology of grounded theory (1978), The Sociology Press, Mill Valley, CA
9. Kippax S., Noble J., Prestage G., Crawford J.M., Campbell D., Baxter D., et al. Sexual negotiation in the AIDS era: negotiated safety revisited. AIDS 11 2 (1997) 191-197
10. Grady C., Dickert N., Jawetz T., Gensler G., and Emanual E. An analysis of US practices of paying research participants. Contemp Clin Trials 26 (2005) 365-375
11. Kresge K. Primer: Understanding community advisory boards. IAVI. Available at: http://www.iavireport.org/vax/english/Vax_2005_5_v7.web.pdf, 2005.
12. WHO/UNAIDS/IAVI International Expert Group. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA. AIDS 2007;21:539-46.
13. Duan N. Listening to consumers and HIV vaccine preparedness. Lancet 365 9465 (2005) 1119-1121
14. Newman P.A. Towards a science of community engagement. Lancet 367 9507 (2006) 302
15. Singh J.A., and Mills E.J. The abandoned trials of pre-exposure prophylaxis for HIV: what went wrong?. PLoS Med 2 9 (2005) 824-827